Daily Cosmetic Research Analysis
Today's most impactful cosmetic-related research spans clinical efficacy of a hybrid HA–CaHA filler with year-long durability, a double-blind half-face trial of a dermocosmetic blend (Encorelane) that improves barrier and inflammatory markers in sensitive skin, and a comprehensive toxicology and exposure review supporting the safety of the UV filter ensulizole at current use levels. Together, these works inform product selection, mechanism-driven skin care, and regulatory safety.
Summary
Today's most impactful cosmetic-related research spans clinical efficacy of a hybrid HA–CaHA filler with year-long durability, a double-blind half-face trial of a dermocosmetic blend (Encorelane) that improves barrier and inflammatory markers in sensitive skin, and a comprehensive toxicology and exposure review supporting the safety of the UV filter ensulizole at current use levels. Together, these works inform product selection, mechanism-driven skin care, and regulatory safety.
Research Themes
- Dermal fillers: durability and safety in aesthetic augmentation
- Sensitive-skin dermocosmetics: anti-inflammatory and barrier-enhancing strategies
- Sunscreen UV filters: toxicology and human exposure assessment
Selected Articles
1. A Prospective, Open-Label, Post Marketing Study of the Safety and Effectiveness of a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable.
In a 140-participant prospective, open-label study, a hybrid hyaluronic acid–calcium hydroxyapatite filler achieved an 82.8% Month-1 MFVDS responder rate with improvements maintained through 12 months. Investigator- and participant-rated GAIS responses were high, FACE-Q scores improved markedly, and safety was acceptable with mostly mild-to-moderate injection-site reactions.
Impact: Provides real-world, year-long effectiveness and safety data for a hybrid filler, informing product selection and patient counseling in aesthetic practice.
Clinical Implications: Supports the use of HA–CaHA for midface augmentation with durable aesthetic improvement up to 12 months and an acceptable safety profile; helps set expectations on responder rates and common adverse events.
Key Findings
- Month-1 MFVDS responder rate was 82.8% and remained high through Month 12.
- Investigator and participant GAIS responder rates were 98.5% and 91.8% at Month 1, remaining high over 12 months.
- FACE-Q Satisfaction with Cheeks (+33.3) and Facial Appearance (+23.8) improved markedly; most adverse events were mild-to-moderate injection-site reactions.
Methodological Strengths
- Prospective design with predefined endpoints and 12-month follow-up
- Multiple validated outcome measures (MFVDS, GAIS, FACE-Q) and exploratory 3D movement tracking
Limitations
- Open-label, uncontrolled design limits causal inference
- Optional touch-ups and variable injection regions may introduce performance and selection biases
Future Directions: Conduct randomized, blinded head-to-head trials versus single-material HA or CaHA, standardize injection protocols, and extend follow-up beyond 12 months with objective volumetric imaging.
BACKGROUND: HA-CaHA is a hybrid injectable combining hyaluronic acid and calcium hydroxyapatite for dual-mode facial soft tissue augmentation. HA-CaHA-L includes 0.3% lidocaine HCL. OBJECTIVE: This prospective, open-label study evaluated the effectiveness and safety of HA-CaHA for treating midface volume deficit. METHODS: Adults rated Moderate to Severe on the Allergan Midface Volume Deficit Scale (MFVDS) received HA-CaHA (n = 110) or HA-CaHA-L (n = 30) in the cheek (primary injection region) and jawline (optional) areas, with optional touch-up 2 weeks later. Follow-up visits occurred at Months 1, 3, 6, 9, and 12. The primary endpoint was the MFVDS responder rate (≥ 1-grade improvement from baseline) at Month 1. Secondary endpoints were the Global Aesthetic Improvement Scale (GAIS) responder rates and change from baseline on FACE-Q Satisfaction with Cheeks and Satisfaction with Facial Appearance. Exploratory endpoints were the Allergan Cheek Smoothness Scale (ACSS) scores and 3D photo-based midface movement tracking. Safety was assessed throughout. RESULTS: At Month 1, MFVDS responder rate was 82.8%, remaining high through Month 12. The GAIS responder rates were 98.5% (investigator-rated) and 91.8% (participant-rated) at Month 1, remaining high through Month 12. FACE-Q scores improved 33.3 (Cheeks) and 23.8 (Facial Appearance) points at Month 1, remaining high through Month 12. ACSS scores peaked at Months 3 (73.7%) and 6 (69.2%), with corresponding skin movement changes. Most participants (95.7%) experienced mild or moderate ISRs. The most common treatment-related AEs were injection site pain (11.4%), injection site mass (10.7%), and headache (7.1%). CONCLUSIONS: HA-CaHA and HA-CaHA-L are effective and well-tolerated for midface soft tissue augmentation, lasting up to 1 year.
2. Efficacy of Encorelane in Enhancing Barrier Function and Reducing Aging Signs in Sensitive Skin.
A double-blind, half-face, 6-week clinical study in 23 sensitive-skin adults showed significant improvements versus placebo in TEWL, firmness (R2, F4), and crow’s feet when using Encorelane. Mechanistically, Encorelane reduced pro-inflammatory cytokines (IL-1α, TNF-α, IL-6, IL-8, PGE2) and increased barrier (AQP3, FLG, LOR, TGM1) and matrix markers in SLS-stressed 3D epidermis.
Impact: Combines mechanistic in vitro evidence with a controlled human half-face trial, supporting a multi-target dermocosmetic strategy for sensitive, aging-prone skin.
Clinical Implications: Supports short-term use of Encorelane-containing formulations to reduce inflammation, enhance barrier function, and improve fine wrinkles in sensitive skin; half-face, blinded results aid clinician confidence in recommending such products.
Key Findings
- In vitro, IL-1α, TNF-α, IL-6, IL-8, and PGE2 decreased while AQP3, FLG, LOR, TGM1 and multiple collagen isoforms and laminin 5 increased (p<0.05).
- In vivo, Encorelane outperformed placebo over 6 weeks in TEWL reduction, firmness metrics (R2, F4), and crow’s feet wrinkle improvement (p<0.05).
- Half-face, double-blind design provides within-subject control to detect meaningful cosmetic effects in sensitive skin.
Methodological Strengths
- Double-blind, half-face controlled human study design
- Mechanistic validation in a 3D SLS-induced epidermal model with multiple biomarkers
Limitations
- Small sample size (n=23) and short duration (6 weeks) limit generalizability and durability assessment
- Study endpoints focus on surrogate and cosmetic outcomes without long-term follow-up
Future Directions: Larger, longer randomized trials across diverse skin types, dose–response optimization, and head-to-head comparisons with benchmark dermocosmetics.
BACKGROUND: Sensitive skin requires targeted care to improve barrier function, reduce inflammation, and manage neurovascular reactivity. OBJECTIVE: Encorelane, a novel ingredient blend of saccharide isomerate, ribose, and fructooligosaccharides, was evaluated for its efficacy in addressing sensitive skin and visible aging signs. METHODS: In vitro: A 3D epidermal model (EpiKutis) with Sodium Lauryl Sulfate (SLS) induction was used to assess cytokines (interleukin 1α [IL-1α], interleukin 6 [IL-6], interleukin 8 [IL-8], tumor necrosis factor α [TNF-α], prostaglandin E2 [PGE2]) and barrier markers (filaggrin [FLG], loricrin [LOR], transglutaminase 1 [TGM1]). Hydration was examined via aquaporin 3 (AQP3) expression levels. Anti-wrinkle efficacy was tested against UVA/UVB exposure, evaluating collagen synthesis and skin matrix components (Collagen types I, III, IV, VII, XVII, Laminin 5, hyaluronic acid [HA], Chondroitin sulfate [CS]). In vivo: A 6-week double-blind, half-face study in 23 sensitive-skin subjects evaluated the clinical effects of Encorelane versus placebo on repair, redness, firmness, and wrinkles. RESULTS: In vitro: Compared to the control group, Encorelane significantly reduced the levels of IL-1α, TNF-α, IL-6, IL-8, and PGE2 (p < 0.05), and significantly increased the levels of AQP3, FLG, LOR, TGM1, collagen types I, III, IV, VII, XVII, and laminin 5 (p < 0.05). In vivo: Compared to the placebo, Encorelane significantly improved TEWL, R2, F4, and crow's feet wrinkles (p < 0.05). CONCLUSION: Encorelane effectively targets both inflammation and aging signs, supporting its use as a dermocosmetic solution for sensitive, aging-prone skin.
3. Comprehensive review of ensulizole toxicology data and human exposure assessment for personal care products.
This comprehensive review synthesizes toxicology and exposure data for ensulizole used in sunscreens, noting authorized maximum concentrations of 3–8% (4% in the US/Canada/Australia) and postmarketing safety signals limited to occasional local skin effects without systemic toxicity. Findings support current regulatory concentrations while highlighting the need to assess cumulative and long-term mixture exposures.
Impact: Addresses a critical safety question for a widely used UV filter, informing regulators, clinicians, and formulators about exposure limits and real-world safety signals.
Clinical Implications: Clinicians can reassure patients regarding systemic safety at authorized concentrations while remaining vigilant for local irritation; formulators can align with global limits and consider cumulative exposure in multi-product use.
Key Findings
- Authorized maximum ensulizole concentrations range from 3–8% globally, capped at 4% in the US, Canada, and Australia.
- Postmarketing clinical safety reports indicate occasional local skin effects without evidence of systemic toxicity.
- The review integrates toxicity and human exposure data relevant to over-the-counter sunscreen use.
Methodological Strengths
- Comprehensive collation of toxicology endpoints and human exposure assessments
- Global regulatory context enables cross-jurisdictional interpretation
Limitations
- Narrative review not explicitly PRISMA-compliant; potential selection bias
- Limited data on long-term cumulative and mixture exposures in vulnerable populations
Future Directions: Prospective biomonitoring and mixture risk assessments across demographics and product-use patterns; standardized reporting of local adverse events in real-world sunscreen use.
A comprehensive review of existing toxicity and human exposure data for the ultraviolet filter ensulizole (2-phenylbenzimidazole-5-sulfonic acid) as currently used in over-the-counter sunscreen formulations was conducted. Authorized maximum ensulizole usage levels in consumer end-use products worldwide range from 3% to 8%, with the maximum usage level limited to 4% in the United States, Canada, and Australia. Postmarketing clinical safety studies of ensulizole have reported only occasional local skin effects, none of which were associated with systemic toxicity. Ensulizole has been investigated